- Home
- REFI vs TNGX Comparison
REFI vs TNGX Comparison
Compare REFI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- TNGX
- Stock Information
- Founded
- REFI 2021
- TNGX 2014
- Country
- REFI United States
- TNGX United States
- Employees
- REFI N/A
- TNGX N/A
- Industry
- REFI Real Estate Investment Trusts
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- TNGX Health Care
- Exchange
- REFI Nasdaq
- TNGX Nasdaq
- Market Cap
- REFI 274.3M
- TNGX 723.2M
- IPO Year
- REFI 2021
- TNGX N/A
- Fundamental
- Price
- REFI $13.37
- TNGX $6.82
- Analyst Decision
- REFI Strong Buy
- TNGX Strong Buy
- Analyst Count
- REFI 3
- TNGX 6
- Target Price
- REFI $20.00
- TNGX $10.00
- AVG Volume (30 Days)
- REFI 130.8K
- TNGX 1.5M
- Earning Date
- REFI 11-06-2025
- TNGX 11-05-2025
- Dividend Yield
- REFI 15.44%
- TNGX N/A
- EPS Growth
- REFI N/A
- TNGX N/A
- EPS
- REFI 1.84
- TNGX N/A
- Revenue
- REFI $56,608,781.00
- TNGX $24,296,000.00
- Revenue This Year
- REFI $9.93
- TNGX $6.56
- Revenue Next Year
- REFI $4.99
- TNGX N/A
- P/E Ratio
- REFI $7.26
- TNGX N/A
- Revenue Growth
- REFI 2.58
- TNGX N/A
- 52 Week Low
- REFI $12.76
- TNGX $1.03
- 52 Week High
- REFI $16.29
- TNGX $10.81
- Technical
- Relative Strength Index (RSI)
- REFI 39.83
- TNGX 52.79
- Support Level
- REFI $13.08
- TNGX $6.25
- Resistance Level
- REFI $14.57
- TNGX $6.90
- Average True Range (ATR)
- REFI 0.32
- TNGX 0.41
- MACD
- REFI -0.12
- TNGX -0.04
- Stochastic Oscillator
- REFI 19.46
- TNGX 49.57
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.